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Abstract
Background
Information about drug utilisation among outpatients in Serbia and Montenegro is scanty, and no publications on 
the topic are available. The objective of this study was thus to evaluate and compare patterns of drug utilisation 
in the Zabljak municipality.
Methods 
Prescriptions for outpatients (n=456) and dispensing records from a local pharmacy in Zabljak for a three-
month period were reviewed retrospectively.
Results
The leading diagnoses were infectious diseases of the respiratory system and hypertension. The total number 
of defined daily doses (DDD) per 1 000 inhabitants per day was 178.75. Cardiovascular drugs (41.139 DDD/1 
000/day), drugs for the gastrointestinal system (36.881 DDD/1 000/day) and antibacterial drugs (18.318 DDD/
1 000/day) were the most frequently prescribed drugs.
Conclusion
The total number of drugs utilised per 1 000 inhabitants per day was within the acceptable range. However, the 
pattern of diagnosis did not correspond to the pattern of drug utilisation. There is a need for intervention in order 
to promote the rational selection and use of drugs among outpatients in Serbia and Montenegro.
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Introduction
Drug utilisation statistics are an im-
portant tool with which to evaluate the 
quality of prescribing in a defined set-
ting.1 Although significant efforts have 
been made to introduce the principles 
of rational drug use worldwide, the situ-
ation is still far from ideal.2,3 There are 
many reasons for this situation, includ-
ing: (1) a lack of national guidelines for 
the treatment of mass diseases in some 
countries; (2) no system for the provi-
sion of continuing medical education in 
some countries; (3) the retention of ob-
solete drugs in the market; (4) medical 
practice not based on evidence; and 
(5) pressure from pharmaceutical com-
panies.4,5 Serbia and Montenegro is a 
country in socio-economical transition, 
with a high burden of poverty and many 
refugees. The country faces some of 
the abovementioned problems.6 The 
aim of this study was to investigate 
patterns of drug use in the semi-rural 
municipality of Zabljak, which could 
be considered a typical municipality in 
Serbia and Montenegro. 
Methods
This is a cross-sectional study of drug 
utilisation in the Zabljak municipality, 
which is located in the mountainous 
area of Serbia and Montenegro and 
has 4 880 inhabitants. The study was 
conducted from January to March 
in 2001. There was only one primary 
care health facility in Zabljak where 
prescribing was done, and only one 
state pharmacy, where prescribed 
drugs were dispensed. During the 
abovementioned period, the following 
data were collected from prescriptions 
and dispensing records: initials, sex 
and age of the patients, diagnosis, 
drugs dispensed, and the doses of the 
drugs. 
Drug utilisation was calculated using 
the methodology of the World Health 
Organization,7 and expressed in de-
fined daily doses (DDDs) per 1 000 
inhabitants per day. The diagnoses 
were classified according to the tenth 
revision of the International Classifica-
tion of Diseases.8 
Results
The total number of patients for the 
study period was 465. Of these, 259 
(56%) were adults (124 males and 135 
females) and 206 (44%) were children 
younger than 14 years (109 boys and 
97 girls). Since Zabljak municipality is 
remote and isolated, the physicians 
only prescribed drugs that were avail-
able in the local pharmacy. The total 
drug utilisation was 178.75 DDD/1 000 
inhabitants/day. The drugs comprising 
90% of the total drug utilisation are 
shown in Table I, classified according 
to the Anatomic-Therapeutic-Chemical 
ATC classification. The diagnoses com-
prising 90% of all diagnoses for both 
adults and children are given in Table 
II. The number of diagnoses (411) was 
less than the number of patients (465); 
the remaining 54 patients did not have 
diagnoses in their dispensing records.
Discussion
Overall drug utilisation in Zabljak was 
not higher than in other countries, 
including developed ones.9 However, 
the patterns of drug utilisation point to 
certain irrationalities. 
The first problem we observed was 
related to the utilisation of anti-hyper-
tensive drugs. The total quantity of 
all anti-hypertensive drugs used was 
about 30 DDD/1 000 inhabitants/day; 
at the same time, only 31 patients were 
diagnosed as having hypertension, 
which implies everyday drug therapy. 
Since Zabljak has   4 880 inhabitants, 
this means that there were about six 
hypertensive patients per 1 000 in-
habitants. At first glance it appeared 
that each hypertensive patient was 
taking on average about five drugs 
with an anti-hypertensive action (diuret-
ics, ACE inhibitors, beta-blockers or 
calcium-channel antagonists). How-
ever, since diuretics and ACE inhibitors 
could also be used for heart failure 
and beta-blockers or calcium-channel 
inhibitors for diseases of the coronary 
artery, these drugs could have been 
used for another four      patients/1 000 
inhabitants/day suffering from these 
two diseases. This leads to an average 
of three anti-hypertensive drugs for the 
patients with hypertension, which is still 
too high. Only exceptional hyperten-
sion should be treated with more than 
two drugs (in about 20% of patients), 
and there is no reason to believe that 
all of the patients required such a regi-
men.10
Over-utilisation was also observed with 
drugs against angina pectoris. Tables 
I and II indicate that there were three 
patients with angina pectoris per 1 000 
inhabitants, while around 15 DDDs of 
anti-anginal drugs were dispensed 
per 1 000 inhabitants every day. Even 
if half of this drug utilisation is ascribed 
to anti-hypertensive treatment (beta 
blockers and calcium-channel antago-
nists also could be used for this indica-
tion), it remains that three to five anti-
anginal drugs were used per patient. 
Since angina pectoris is treated mostly 
with a combination of two anti-anginal 
drugs, it seems that polypharmacy oc-
curred.11
Regarding antibiotic utilisation, it is 
clear from Table I that the total con-
sumption was around 18 DDDs/1 000 
inhabitants/day. About 280 patients 
(both adults and children) were suffer-
ing from infections, and if one consid-
ers the five-day duration of a course of 
treatment for an infection, it means that 
there were 90/5 = 18 disease courses 
during the study period. Furthermore, 
it means that 280/18 = 15.6 patients 
had an infection every day. Since 18 
DDDs were utilised for these 15.6 pa-
tients, it appears that each patient with 
an infection was receiving at least one 
antibiotic. According to other studies, 
at most 50% of patients with an infec-
tion should receive antibiotics,12 which 
points to over-prescribing of antibiotics 
in this case.
Vitamins were also over-utilised, at 
20 DDDs/1 000 inhabitants/day. How-
ever, over-utilisation of vitamins is not 
an isolated phenomenon specific to 
Zabljak. In a survey done in Germany, 
4 030 persons aged from 18 to 79 
were asked about their dietary habits, 
including vitamin and mineral supple-
ment use. About 43% of the population 
reported using supplements at least 
once in the observation period of 12 
months.13 In Spain, 34.6% of all drugs 
sold in community pharmacies are 
vitamins.14 
The utilisation of drugs that decrease 
hydrochloric acid secretion in the 
stomach (ranitidine, famotidine and 
omeprazole) was also inappropriately 
high. Only 10 patients had an indication 
for the use of these drugs (five patients 
with ulcer and five patients with gastri-
tis, which is equal to two patients/1 000 
inhabitants/day), while 10 DDDs/1 000 
inhabitants/day of these drugs were 
utilised. This means that eight out of 
10 patients who were taking H2 block-
ers or a proton pump inhibitor had no 
rational reason to do so. This figure is 
much higher than the situation in pri-
mary care in the USA, where around 
61% of patients with definite indications 
were found to be taking H2 blockers or 
proton pump inhibitors.15
Finally, anti-asthmatic medication 
was dispensed in higher quantities 
than actually needed. There were 
1.6 patients with bronchial asthma or 
chronic obstructive pulmonary disease 
per 1 000 inhabitants – the only ones 
who may have reason to use anti-asth-
matic drugs. Even if each patient was 
SA Fam Pract 2007:49(1)16 b
Original Research
Table I: Drugs whose utilisation comprised 90% of the total drug utilisation (in DDD/1 000 inhabitants/ day) in Zabljak municipality during a 
three-month period 
Group A Drugs for gastrointestinal tract and metabolism DDD/1 000 inhabitants/day





A06 Drugs for Constipation
Bisacodyl 0.847
A06 total 0.847
A07 Antidiarrhoeal, anti-infectious and intestinal anti-inflammatory drugs
Nystatin 0.649
Loperamide 0.601
Bacillus IP 5832 1.202
A07 total 2.452






Vitamin B group 1.229
Ascorbic acid 11.202





A group: 36.881 DDD/1 000 inhabitants/day




B03 Drugs used in anaemias
Ferrous sulphate 0.717
B03 total 0.717
B group: 1.229 DDD/1 000 inhabitants/day
C group Cardiovascular drugs DDD/1 000 inhabitants/day
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C group Cardiovascular drugs DDD/1 000 inhabitants/day
C04 total 1.22















C group: 41.139 DDD/1 000 inhabitants/day








H group: 1.889 DDD/1 000 inhabitants/day










J group: 18.318 DDD/1 000 inhabitants/day
M group Drugs for musculoskeletal disorders DDD/1 000 inhabitants/day









M group: 25.742 DDD/1 000 inhabitants/day
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N group: 11.669 DDD/1 000 inhabitants/day
R group Drugs for respiratory system DDD/1 000 inhabitants/day
R01 Nasal formulations













R group: 21.478 DDD/1 000 inhabitants/day
S group Drugs for eye and ears DDD/1 000 inhabitants/day
S01 Drugs for eye
Dexamethasone plus neomycin 0.763
Naphazoline 1.764
S01 total 2.527
S group: 2.527 DDD/ 1000 inhabitants/day
TOTAL 90% UTILISATION: 160.872 DDD/1 000 inhabitants/day
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J02 Acute pharyngitis 156 (37.8%) 77 79
J00 Acute nasopharyngitis (“common cold”) 41 (9.8%) 20 21
I10 Primary hypertension 31 (7.4%) 26 5
J20 Acute bronchitis 27 (6.5%) 15 12
R50 Fever of unknown origin 23 (6.4%) 12 11
R05 Cough 16 (3.8%) 8 8
I20 Angina pectoris 15 (3.5%) 7 8
N39 Urinary tract infection 12 (2.9%) 7 5
J01 Acute sinusitis 11 (2.7%) 4 7
M54 Back pain 10 (2.4%) 4 6
J18 Pneumonia 10 (2.4%) 4 6
R51 Headache 8 (1.9%) 4 4
K26 Peptic ulcer disease 5 (1.2%) 2 3
K29 Gastritis 5 (1.2%) 3 2
R55 Syncope 5 (1.2%) 3 2
H10 Conjunctivitis 5 (1.2%) 4 1
G40 Epilepsy 4 (1%) 3 1
J44 Chronic obstructive pulmonary disease (COPD) 4 (1%) 1 3
J45 Asthma 4 (1%) 4 0
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using three different anti-asthmatic 
drugs, this would amount to 5 DDDs/1 
000 inhabitants/day. Yet 12 DDDs/1 
000 inhabitants/day were being used 
(dispensed), probably because the 
patients were creating personal drug 
stocks. This practice should not be 
tolerated, because it bears two nega-
tive consequences: a drug overdose 
or poisoning becomes more possible, 
and the drug budget is not distributed 
evenly throughout the fiscal year.16 
Conclusion
It would appear that drugs are not be-
ing used rationally in this small, isolated 
community. This leads to the need for 
significant interventions in the educa-
tion of general practitioners and for 
the adoption of a clear drug policy in 
primary care in the Zabljak municipality 
of Serbia and Montenegro.16 
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